News Quantified

SUPN – supernus pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Supernus Pharmaceuticals (SUPN) was given a new $65.00 price target by Craig Hallum.

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript [Seeking Alpha]

Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]

Supernus Pharmaceuticals's (NASDAQ:SUPN) Q4 CY2025: Strong Sales [Yahoo! Finance]

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

2.4%

MISS

-17.4%

MISS

13.1%

BEAT

-4.6%

MISS

Form 144 SUPERNUS PHARMACEUTICALS Filed by: GEMAYEL GEORGES

Form 4 SUPERNUS PHARMACEUTICALS For: Feb 28 Filed by: Khattar Jack A.

Form 4 SUPERNUS PHARMACEUTICALS For: Feb 28 Filed by: DEC TIMOTHY C

Form 4 SUPERNUS PHARMACEUTICALS For: Feb 28 Filed by: Mottola Frank

Form 10-K SUPERNUS PHARMACEUTICALS For: Dec 31

Top News Gainers

4/28 Supernus to Acquire CNS Portfolio from US WorldMeds 19.0%

3/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 6.8%

11/7 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. 6.1%

4/3 Form 8-K SUPERNUS PHARMACEUTICALS For: Mar 30 5.7%

11/8 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at Berenberg Bank from a "buy" rating to a "hold" rating. 5.1%

8/27 Form 4 SUPERNUS PHARMACEUTICALS For: Aug 23 Filed by: Khattar Jack A. 5.1%

3/30 Supernus Provides Business Update 4.8%

3/4 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.4%

6/25 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.0%

4/24 Supernus to Host First Quarter Results Earnings Conference Call 3.3%

Top News Decliners

11/5 Q3/2019 9/30/2019 EPS 0.540 ZacksConsensus 0.590 ActVsEst (0.050) - Miss -31.6%

8/6 Q2/2019 6/30/2019 EPS 0.610 ZacksConsensus 0.560 ActVsEst 0.050 - Beat -15.0%

2/25 Supernus Announces Fourth Quarter and Full Year 2019 Financial Results -14.9%

2/26 Why Supernus Pharmaceuticals Plunged 15% Today [The Motley Fool] -7.8%

8/27 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.0%

5/7 Form 8-K SUPERNUS PHARMACEUTICALS For: May 07 -3.5%

5/29 Supernus to Present at the Jefferies 2019 Global Healthcare Conference -3.5%

9/25 Form 8-K SUPERNUS PHARMACEUTICALS For: Sep 25 -3.4%

1/23 Form 8-K SUPERNUS PHARMACEUTICALS For: Jan 21 -2.6%

4/30 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) had its price target raised by analysts at Piper Sandler from $17.00 to $25.00. They now have a "neutral" rating on the stock. -2.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day